Masthead

nCounter®
PanCancer Progression Panel

Masthead

Helping Your Research

Cancer progression involves multiple processes and mechanisms that are highly interconnected. The nCounter PanCancer Progression Panel lets you perform multiplex gene expression analysis with 770 genes from each step in the cancer progression process including: angiogenesis, extracellular matrix remodeling (ECM), epithelial-to-mesenchymal transition (EMT) and metastasis. 

  • Comprehensive gene expression analysis of cancer progression 
  • Quantify gene expression of metastatic growth and suppressor genes 
  • Rapidly and easily screen samples for biomarker discovery or drug mechanism of action to support your research 
  • Customizable with up to 55 additional user-defined genes with Panel Plus option 
  • 3D-enabled for multi-analyte analysis with Vantage 3D™ Assays

Inspired by systems biology approaches to cancer research, NanoString’s 360 Series Panel Collection gives you a 360° view of gene expression by combining carefully-curated content involved in the biology of the tumor, microenvironment, and the immune response into a single holistic assay. Each panel contains the 18-gene Tumor Inflammation Signature (TIS) that measures a peripherally-suppressed, adaptive immune response and has been shown to correlate with response to checkpoint inhibitors.

How It Works

Progression Panel Gene Coverage

The following is a pictorial description of the processes and key genes included in the PanCancer Progression Panel

Panel Selection Tool

Find the gene expression panel for your research with easy to use panel pro

Find Your Panel

Product Information

Specifications
Catalog Information
Product Comparison
Specifications
Catalog Information
Product Comparison

360 Series Product Comparison

Fully-annotated gene lists in Excel format are available for each of the 360 Panels. The table below compares the biology coverage of the 360 Panels across the tumor, microenvironment, and the immune response to that of the PanCancer Panels Collection.

Related Resources

See All Resources
Product Bulletin Hallmarks of Cancer – Product Bulletin
Supplement Hallmarks of Cancer Supplement
Whitepaper Multiplexed Cancer Progression Analysis – Whitepaper

Publications

View All Publications

Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression.

Medulloblastoma (MB) is the most common primary malignant pediatric brain cancer. We recently identified novel roles for the MEK/MAPK pathway in regulating human Sonic Hedgehog (SHH) MB tumorigenesis.

Immune suppression in the tumor-draining lymph node corresponds with distant disease recurrence in patients with melanoma.

Immune checkpoint blockade (ICB) using anti-PD-1/PD-L1 and anti-CTLA-4 antibodies significantly enhances survival in metastatic melanoma patients and has recently been shown to prolong relapse-free survival in stage III and high-risk stage II melanoma patients ( Eggermont et al. , 2018; Luke et al.

Multidimensional Immunophenotyping of Intraductal Papillary Mucinous Neoplasms Reveals Novel T Cell and Macrophage Signature.

Background: Intraductal papillary mucinous neoplasms (IPMN) are the only radiographically identifiable precursor to pancreatic adenocarcinoma, yet little is known about how these lesions progress to cancer. Inflammation has been associated with dysplastic progression; however, the cause and composition of this inflammation remains poorly characterized.

Skysphere

Contact Us

Have questions or simply want to learn more?

Contact our helpful experts and we’ll be in touch soon.

Contact Us